On the upside
Athersys (Nasdaq: ATHX) was granted a patent for the isolation and expansion of non-embryonic multipotent stem cells.
Fourth quarter earnings for Baidu (Nasdaq: BIDU) surged to beat expectations as revenue soared.
Correction Corp. of America (NYSE: CXW) reported higher fourth quarter earnings the topped estimates as a greater inmante population boosted revenue.
On the downside
Genzyme (Nasdaq: GENZ) and Isis Pharmaceuticals (Nasdaq: ISIS) reported that phase 3 clinical trial of their cholesterol treatment mipomersen met study goals but the stock prices fell.
Micron Technology (Nasdaq: MU) will acquire rival Numonyx in an all stock deal valued at approximately $1.27 billion.
While Sprint (NYSE: S) narrowed fourth quarter losses, the results missed expectations.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 2 on the NYSE and by more than 5 to 2 on Nasdaq. The Russell 2000 which tracks small cap stocks dropped 7 points to 587.
